Nykode Therapeutics AS (OSL:NYKD) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:NYKD Nykode Therapeutics AS OSL:NYKD
48 GF Score
Price kr3.20
GF Value kr6.45
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

OSL:NYKD
48GF Score
Nykode Therapeutics AS OSL:NYKD
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nykode Therapeutics AS (OSL:NYKD) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of kr3.20 is trading 50.4% below its estimated GF Value™ of kr6.45. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for OSL:NYKD:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr6.45 vs. price of kr3.20 (50.4% below fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the OSL:NYKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score

Get the complete analysis for OSL:NYKD

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.20
Price
kr6.45
GF Value